Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. [electronic resource]
Producer: 20011004Description: 2840-53 p. digitalISSN:- 1078-0432
- Adult
- Aged
- Animals
- Antineoplastic Agents, Phytogenic -- therapeutic use
- Biopsy
- Blood Vessels -- drug effects
- Blotting, Northern
- Cadherins -- analysis
- Carcinoma, Transitional Cell -- drug therapy
- Cell Movement -- drug effects
- Collagen
- Collagenases -- drug effects
- Dose-Response Relationship, Drug
- Drug Combinations
- Drug Synergism
- Endothelial Growth Factors -- genetics
- Female
- Fibroblast Growth Factor 2 -- genetics
- Follow-Up Studies
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- In Situ Hybridization
- Interferon-alpha -- therapeutic use
- Interleukin-8 -- genetics
- Laminin
- Lymphokines -- genetics
- Male
- Matrix Metalloproteinase 9 -- analysis
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Middle Aged
- Neoplasm Invasiveness
- Neoplasm Metastasis -- pathology
- Neoplasm Staging
- Neovascularization, Pathologic -- prevention & control
- Paclitaxel -- therapeutic use
- Prognosis
- Proteoglycans
- RNA, Messenger -- drug effects
- Tumor Cells, Cultured
- Urinary Bladder -- chemistry
- Urinary Bladder Neoplasms -- drug therapy
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factors
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.